International Journal of Pharmacy
Journal Homepage: http://www.pharmascholars.com

Short Communication **CODEN: IJPNL6**

Formulation design,optimization and in vitro charectarization of acyclovir-loaded solid lipid nanoparticles

Samrat Bose*

Assistant Professor,Department of Pharmacy ,Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, India

Corresponding author email: **samrat.bose@gnipst.ac.in**

Received on: 01-04-2021; Revised on: 15-04-2021; Accepted on: 22-04-2021

ABSTRACT

The objective of this examination was to configuration, upgrade, and describe Acyclovir-stacked strong lipid nanoparticles (ACV-SLNs) concerning molecule size, zeta potential, entanglement productivity, and delivery profile. Full factorial plan (23) was applied and the free factors were surfactant type (Tween 80 and Pluronic F68), lipid type (Stearic corrosive and Compritol 888 ATO), and co-surfactant type (Lecithin and Sodium deoxycholate). The microemulsion procedure was utilized trailed by ultrasonication. The ACV-SLNs had a molecule size scope of around 172–542 nm. The polydispersity record (PDI) was discovered to be somewhere in the range of 0.193 and 0.526. Zeta potential was in the scope of – 25.7 to – 41.6 mV demonstrating great actual security. Ensnarement effectiveness esteems were in the scope of 56.3–80.7%. The medication discharge energy of the readied details was best fitted to Higuchi dissemination model. In the wake of putting away ACV-SLNs at refrigerated condition (5 ± 3°C) and room temperature (25 ± 2°C) for about a month; we contemplated the adjustment of the molecule size, PDI, and zeta potential. The chose upgraded detailing (F4) was containing Compritol, Pluronic F68, and Lecithin. These results indicated the successful application of this design to optimize the ACV-SLNs as a promising delivery system.

Keywords: Acyclovir,Solid loipid nanoparticle,Factorial design

INTRODUCTION

The objective of this examination was to configuration, streamline, and describe Acyclovir-stacked strong lipid nanoparticles (ACV-SLNs) concerning molecule size, zeta potential, entanglement effectiveness, and delivery profile. Full factorial plan (23) was applied and the free factors were surfactant type (Tween 80 and Pluronic F68), lipid type (Stearic corrosive and Compritol 888 ATO), and co-surfactant type (Lecithin and Sodium deoxycholate). The microemulsion procedure was utilized trailed by ultrasonication. The ACV-SLNs had a molecule size scope of around 172–542 nm. The polydispersity file (PDI) was discovered to be somewhere in the range of 0.193 and 0.526. Zeta potential was in the scope of – 25.7 to – 41.6 mV showing great actual steadiness. Ensnarement proficiency esteems were in the scope of 56.3–80.7%. The medication discharge energy of the readied definitions was best fitted to Higuchi dissemination model. Subsequent to putting away ACV-SLNs at refrigerated condition (5 ± 3 °C) and room temperature (25 ± 2 °C) for about a month; we examined the adjustment in the molecule size, PDI, and zeta potential. The chose upgraded detailing (F4) was containing Compritol, Pluronic F68, and Lecithin. These outcomes demonstrated the effective use of this plan to upgrade the ACV-SLNs as a promising conveyance framework.

DESCRIPTION

Synthetic substances and Drugs ACV was bought from Hetero Labs, Hyderabad, India. Different synthetic compounds like stearic corrosive, glycerol, microcrystalline cellulose, and sorbitol sodium were bought from The Madras Pharmaceuticals, Arrangement of ACV SLNs The arrangement of ACV SLN depended on emulsification and low-temperature hardening strategy. Lipid stage (0.753% w/w) was readied by liquefying stearic corrosive in ethanol at 80°C, to which the Epikuron 200 (3.9% w/w) was added and mixed with ACV in 2 ml of dimethyl sulfoxide for 3 min followed

by sonication and known measure of fluid sodium taurocholate (13.8% w/w) which kept up at 80°C was included these blends, mixing (Remi Engine Ltd., Mumbai) at 3000 rpm for 20–30 min, brings about the arrangement of O/W emulsion. The warm microemulsion was then moved into super cold water (2–3°C) dropwise with persistent mixing for 3 h to shape drug-stacked SLNs. The proportion between the microemulsion and the scattering medium was about 1:10, 1:20, and 1:30. The SLN scattering was at that point washed twice with twofold refined water. The ACV SLNs suspension was put away at 0–4°C for long storage.

The ensnarement proficiency of the compound was dictated by estimating the grouping of free ACV in the scattering medium. The SLN suspension was ultracentrifuged at 4000 rpm for 30 min at 4°C temperature utilizing Remi cooling axis to separate the free medication. The measure of free ACV was decided free supernatant by bright (UV) spectrophotometer against clear at 255 nm. The examination was made in three-fold. The medication capture efficiencies were determined utilizing the accompanying condition.

An amount of chosen plan comparable to 25 mg of the ACV was taken in the dialysis pack (cellophane layer, atomic weight cutoff 10,000–12,000 Da; HiMedia). The dialysis sack was then suspended in a flagon containing 100 ml of 0.1 N HCl on an attractive stirrer at 37 ± 0.5°C at 100 rpm. Required amount (5 ml) of the medium was removed at explicit time-frames (1, 2, 3, 4, 6, 8, 10, 12, 24, and 32 h) also, a similar volume of disintegration medium was supplanted in the carafe to keep a steady volume. The removed examples were separated and afterward 5 ml filtrate was made up to volume with 100 ml of 0.1 N HCl. The examples were examined for drug discharge by estimating the absorbance at 252 nm utilizing an UV/ obvious spectrophotometer. The component of medication discharge from nanoparticles is dictated by various physical-compound marvels. The normal rate discharge was fitted into various delivery models: Zero request, first request, what's more, Higuchi's square root plot. The models giving a connection coefficient near solidarity were taken as the request of delivery.

CONCLUSION

ACV-loaded nanoparticles were prepared by the hot homogenization method. In vitro drug release study of the nanoformulation showed 78% release, respectively, in 35 h and the same was 58% in the marketed formulation. The in vitro release profile of ACV from nanoparticles has shown a sustained release following zero-order kinetic with diffusion mechanism. Drug:lipid ratio and concentration of surfactant were found to influence the percentage drug release of ACV-loaded SLNs. These preliminary results indicate that ACV-loaded SLNs could be effective in sustaining drug release for a prolonged period. The results demonstrated the effective use of ACV-loaded SLNs as a controlled release preparation for the treatment of viral infections.

REFRENCES

1. Suresh N, Kumar BS, Shekar DS, Ramnath KV, Kulkarni TG, Suresh B. Formulation and evaluation of oral sustained release suspensions using ethyl cellulose microcapsules containing propranolol hydrochloride using ion exchange resinates. Asian J Chem 2007; 19:2757.
2. Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 1982; 73:7-13.
3. Furman PA, St Clair MH, Fyfe JA, Rideout JL, Keller PM, Elion GB. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl) guanine and its triphosphate. J Virol 1979; 32:72-7.
4. Sankar R, Jain SK. Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: A mechanistic study. Drug Des Devel Ther 2013; 7:1455-69.
5. Bhosale UV, Devi VK. Preparation and in vitro evaluation loaded eudragit RLPO nanoparticles as sustained release carriers. RGUHS J Pharm Sci 2011; 1:85-92.
6. Nilesh J, Ruchi J, Navneet T, Brigham PG, Deepak KJ, Jeetendra B. Nanotechnology: A safe and effective drug delivery system. Asian J Pharm Clin Res 2010; 3:1974-2441.